ribavirin has been researched along with danoprevir in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (88.24) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Deutsch, M; Papatheodoridis, GV | 1 |
| Blatt, L; Bradford, W; Forestier, N; Guyader, D; Larrey, D; Marcellin, P; Patat, A; Porter, S; Rouzier, R; Seiwert, SD; Smith, P; Zeuzem, S | 1 |
| Chang, L; Gane, EJ; Horban, A; Nájera, I; Rouzier, R; Sampeur, P; Shulman, NS; Smith, P; Stedman, C; Tran, JQ; Wiercinska-Drapalo, A; Zhang, Y | 1 |
| Bradford, W; Forestier, N; Guyader, D; Larrey, D; Lim, S; Marcellin, P; Patat, A; Porter, S; Qin, X; Rouzier, R; Seiwert, SD; Smith, PF; Zeuzem, S | 1 |
| Benhamou, Y; Boyer, N; Carenco, C; Guyader, D; Larrey, D; Marcellin, P; Pageaux, GP; Rouzier, R | 1 |
| Balart, L; Box, T; Brunda, M; Buggisch, P; Cooper, C; Ferenci, P; Hooper, G; Labriola-Tompkins, E; Larrey, D; Lawitz, E; Le Pogam, S; Lim, CY; Marcellin, P; Nájera, I; Navarro, MT; Shulman, NS; Terrault, NA; Thomas, D; Weltman, M; Yetzer, ES; Yoshida, E; Zhang, Y | 1 |
| Brennan, BJ; Gane, EJ; Kulkarni, R; Larrey, DG; Le Pogam, S; Morcos, PN; Nájera, I; Petric, R; Rouzier, R; Shulman, NS; Smith, P; Tran, JQ; Wiercinska-Drapalo, A; Yetzer, ES; Zhang, Y | 1 |
| Ballester, R; Bernaards, C; Bertasso, A; Dwyer, C; Gane, EJ; Hammond, J; Kindrick, A; Marcellin, P; Morcos, PN; Nájera, I; Pockros, PJ; Shikhman, A; Shulman, NS; Smith, P; Stancic, S; Tong, X; Yetzer, ES; Zeuzem, S; Zhou, J | 1 |
| Berak, H; Eng, S; Feld, JJ; Foster, GR; Hooper, GJ; Jablkowski, M; Jacobson, IM; Jensen, DM; Kulkarni, R; Le Pogam, S; Lim, CY; Nájera, I; Navarro, MT; Perez-Gomez, HR; Pol, S; Scalori, A; Shahdad, S; Shulman, NS; Tam, E; Tavel, JA; Vierling, JM; Yetzer, ES; Yoshida, EM | 1 |
| Brennan, B; Canini, L; Chatterjee, A; Guedj, J; Lemenuel-Diot, A; Perelson, AS; Smith, PF | 1 |
| Brunda, M; Chu, T; Elston, R; Gane, EJ; George, J; Glavini, K; Hammond, JM; Jensen, DM; Le Pogam, S; Nájera, I; Passe, S; Piekarska, A; Rodriguez, I; Zeuzem, S | 1 |
| Brennan, BJ; Eng, S; Gane, EJ; Hassanein, T; Kupcova, V; Le Pogam, S; Mazur, W; Morcos, PN; Rouzier, R; Scalori, A; Stedman, CA; Thommes, J; Voulgari, A | 1 |
| Brennan, BJ; Hill, G; Kao, JH; Le Pogam, S; Lee, Y; Li, H; Najera, I; Sheen, IS; Tanwandee, T; Thommes, JA; Thongsawat, S; Tung, SY; Wu, JJ; Zhou, J | 1 |
| Chen, CY; Chen, MY; Chen, Q; Kao, JH; Peng, CY; Tang, H; Wu, JJ; Yu, ML | 1 |
| Keam, SJ; Markham, A | 1 |
| Feng, K; Huang, P; Ke, L; Lin, C; Liu, J; Pan, S; Yang, X; Zeng, Y | 1 |
1 review(s) available for ribavirin and danoprevir
| Article | Year |
|---|---|
Danoprevir: First Global Approval.
Topics: Antiviral Agents; China; Cyclopropanes; Dose-Response Relationship, Drug; Drug Approval; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
12 trial(s) available for ribavirin and danoprevir
| Article | Year |
|---|---|
Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Carrier Proteins; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Serine Proteinase Inhibitors; Sulfonamides; Viral Load; Viral Nonstructural Proteins | 2011 |
Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.
Topics: Adult; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Time Factors | 2011 |
Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.
Topics: Antiviral Agents; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Sulfonamides; Viral Nonstructural Proteins | 2011 |
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Topics: Adult; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Epoxy Compounds; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Polyethylene Glycols; Proline; Pyridines; Recombinant Proteins; Ribavirin; Sulfonamides | 2013 |
Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Cyclopropanes; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Mutation; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2014 |
Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study.
Topics: Adult; Aged; Cyclopropanes; Deoxycytidine; Electrocardiography; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides | 2015 |
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
Topics: Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome | 2015 |
A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.
Topics: Antiviral Agents; Cyclopropanes; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Models, Theoretical; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2015 |
Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study.
Topics: Adult; Antiviral Agents; Australia; Benzothiadiazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; New Zealand; Phenotype; Proline; Quinolones; Remission Induction; Ribavirin; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; United States; Viral Load | 2016 |
Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis.
Topics: Antiviral Agents; Cyclopropanes; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Ritonavir; Sulfonamides; Treatment Failure | 2016 |
Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Young Adult | 2016 |
Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study.
Topics: Administration, Ophthalmic; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome | 2018 |
4 other study(ies) available for ribavirin and danoprevir
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection.
Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Cyclopropanes; Dogs; Drug Evaluation, Preclinical; Drug Therapy, Combination; Haplorhini; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Polyethylene Glycols; Proline; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Ribavirin; Ritonavir; Sulfonamides; Viral Nonstructural Proteins | 2010 |
Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; Sulfonamides; Time Factors; Treatment Outcome; Viral Load | 2012 |
Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China.
Topics: Adult; Antiviral Agents; China; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2021 |